<DOC>
	<DOCNO>NCT02251990</DOCNO>
	<brief_summary>This randomize , parallel-group , placebo-controlled , multi-site , multinational , double-blind follow open label period , Phase 3 trial 100 mg grazoprevir ( MK-5172 ) combination 50 mg elbasvir ( MK-8742 ) ( grazoprevir/elbasvir fixed-dose combination [ FDC ] ) treatment-naïve ( TN ) participants chronic hepatitis C virus ( HCV ) , genotype ( GT ) 1 , 4 6 infection . The primary hypothesis proportion participant receive grazoprevir/elbasvir FDC immediate treatment arm achieve SVR12 ( Sustained Virologic Response 12 week end study therapy ) superior reference rate 73 % .</brief_summary>
	<brief_title>Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) Combination Treatment-Naïve Hepatitis C Virus Participants ( MK-5172-067 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Has document chronic HCV GT1 , GT4 , GT6 ( evidence nontypeable mixed genotype ) infection Has cirrhosis liver Is abstinent us acceptable method ( ) contraception Has evidence decompensated liver disease Is coinfected hepatitis B virus human immunodeficiency virus ( HIV ) Shows evidence hepatocellular carcinoma ( HCC ) evaluation HCC Has clinicallyrelevant drug alcohol abuse within 12 month screen Is pregnant breastfeeding Has condition abnormality might confound result trial pose additional risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>